Inflammatory aging may finally have a precision target. The accumulation of damaged DNA fragments within aging cells triggers chronic inflammation through overactive cellular alarm systems, contributing to conditions like late-onset rheumatoid arthritis. This discovery points to a potentially transformative intervention strategy that could address aging-related inflammation at its molecular source. Chinese researchers have engineered an innovative dual-component vaccine system that simultaneously tackles cytoplasmic DNA accumulation from multiple angles. The microsphere platform delivers TREX1 mRNA via specialized lipid nanoparticles while co-releasing DNase I enzyme through polydopamine carriers. This coordinated approach restores the cell's natural DNA cleanup mechanisms while neutralizing inflammatory DNA fragments that escape into surrounding tissues. Testing in aged rats with rheumatoid arthritis showed significant reduction in joint swelling and tissue inflammation. The intervention specifically dampened the cGAS-STING pathway, a key inflammatory cascade that becomes hyperactive with age. Importantly, the treatment modulated various T cell populations involved in autoimmune responses. This represents a notable advance in targeting the fundamental mechanisms underlying inflammaging—the chronic low-grade inflammation that drives multiple age-related diseases. However, several limitations require consideration. The study used animal models rather than human subjects, and the long-term safety profile of sustained mRNA delivery remains unclear. The approach also requires further validation in diverse inflammatory conditions beyond arthritis. While promising as a proof-of-concept for precision anti-aging interventions, clinical translation will need to demonstrate both efficacy and safety in human inflammatory aging contexts.